In an interview with the newspaper Die Welt, HanseMerkur CEO Eberhard Sautter says of the PanTum Detect®: "The test contained in our 'Krebs-Scan' has therefore closed a gap."
The Shield test from US company Guardant Health is the first blood test for the early detection of cancer to receive important FDA approval in the USA. Shield has been approved as a primary screening option for colorectal cancer.
DUP magazine reports: The gene TKTL1 controls cell division. It could also revolutionize the early detection and treatment of cancer.
Following pandemic-related declines, there is once again a positive trend regarding participation in cancer screening examinations.
Apo10 and TKTL1 in blood macrophages could detect lung cancer early. A study proves their high diagnostic value.
The case of a 53-year-old woman who – as part of a PanTum Detect® study – was diagnosed with lung cancer which was successfully removed surgically, has been published as a case study in Frontiers in Oncology.
Publication of the study results of a prospective, clinical study with over 5,000 participants led by the University Medical Centre Hamburg-Eppendorf.